CMA
AMPH icon

Cedar Mountain Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

Cedar Mountain Advisors’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$20 – 1178
2026
Q1 		$20 Buy
+1
New +$24 ﹤0.01% 1142

Other funds holding AMPH

LG
LAM Group Lake Oswego, Oregon $201M AUM 22.35% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
SWP
Significant Wealth Partners Cary, Illinois $92.4M AUM 9.22% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.46B AUM 21.89% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
1IA
1620 Investment Advisors Plymouth, Massachusetts $161M AUM 30.15% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Cedar Mountain Advisors's AMPH Position: Q2 2026 in Review

Cedar Mountain Advisors sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2026, closing a stake of 1 share — an estimated $20 sold.

Cedar Mountain Advisors first reported a position in AMPH in Q1 2026 and held it in 1 quarter. The position peaked at $20 in Q1 2026. 20 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

  • Cedar Mountain Advisors reported no remaining Amphastar Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Cedar Mountain Advisors sold 1 Amphastar Pharmaceuticals share in Q2 2026, an estimated $20.
  • Cedar Mountain Advisors first reported a position in Amphastar Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Cedar Mountain Advisors's Amphastar Pharmaceuticals position peaked at $20 in Q1 2026.
  • 20 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.